Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 5/2009

01-10-2009 | Original Article

Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma

Authors: Gaetano Corazzelli, Gaetana Capobianco, Manuela Arcamone, Pier Ferruccio Ballerini, Emilio Iannitto, Filippo Russo, Ferdinando Frigeri, Cristina Becchimanzi, Gianpaolo Marcacci, Annarosaria De Chiara, Antonio Pinto

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2009

Login to get access

Abstract

Purpose

To determine the efficacy and safety of the combination of gemcitabine plus oxaliplatin, with and without rituximab, in patients with relapsed/refractory B-cell lymphoma unsuitable for high dose therapy.

Methods

Patients were prospectively enrolled in two subsequent trials, GEMOX [gemcitabine (1200 mg/m2, days 1 and 8) and oxaliplatin (120 mg/m2, day 2), three-weekly] and R-GEMOX [rituximab (375 mg/m2, day 1), gemcitabine (1200 mg/m2, day 1) and oxaliplatin (120 mg/m2, day 2), bi-weekly], up to six courses.

Results

Sixty-two patients were enrolled: GEMOX [n = 30; median age, 66 years (range, 46–85); previous chemotherapy ≥2, 70%; PS ECOG ≥ 2, 57%]; R-GEMOX [n = 32; median age, 65 years (range 32–79); previous chemotherapy ≥2, 75%; PS ECOG ≥ 2, 47%]. Overall and complete response rates were 57 and 30% (95% CI, 15–49) for GEMOX and 78 and 50% (95% CI, 32–68) in R-GEMOX, respectively. Grade 3/4 neutropenia occurred in 57 and 47% of cycles and grade 3/4 thrombocytopenia in 26 and 17% of courses for GEMOX and R-GEMOX, respectively. At 42 months, the failure-free survival (FFS) was 7% (95% CI, 0–16) for GEMOX and 28% (95% CI, 9–47) for R-GEMOX (P = 0.014), with overall survivals of 7 (95% CI, 0–16) and 37% (95% CI, 20–55), respectively (P = 0.016).

Conclusions

Both regimes showed good tolerability and appealing response rates. FFS was more prolonged in R-GEMOX, but patients continuously relapsed without a clear plateau on survival curves.
Literature
1.
Seyfarth B, Josting A, Dreyling M, Schmitz N (2006) Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease. Br J Haematol 133(1):3–18PubMedCrossRef
2.
Schulz H, Bohlius JF, Trelle S, Skoetz N, Reiser M, Kober T et al (2007) Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 99(9):706–714PubMedCrossRef
3.
Moskowitz CH, Bertino JR, Glassman JR, Hedrick EE, Hunte S, Coady-Lyons N et al (1999) Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin’s lymphoma. J Clin Oncol 17(12):3776–3785PubMed
4.
Zinzani PL, Tani M, Molinari AL, Stefoni V, Zuffa E, Alinari L et al (2002) Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients. Haematologica 87(8):816–821PubMed
5.
Rodriguez-Monge EJ, Cabanillas F (1997) Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience. Hematol Oncol Clin North Am 11(5):937–947PubMedCrossRef
6.
Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A et al (2004) Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 103(10):3684–3688PubMedCrossRef
7.
Witzig TE, Geyer SM, Kurtin PJ, Colgan JP, Inwards DJ, Micallef IN et al (2008) Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group. Leuk Lymphoma 49(6):1074–1080PubMedCrossRef
8.
9.
Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V (1995) Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22(4 Suppl 11):3–10PubMed
10.
Dumontet C, Morschhauser F, Solal-Celigny P, Bouafia F, Bourgeois E, Thieblemont C et al (2001) Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin’s lymphoma. Br J Haematol 113(3):772–778PubMedCrossRef
11.
Fossa A, Santoro A, Hiddemann W, Truemper L, Niederle N, Buksmaui S et al (1999) Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol 17(12):3786–3792PubMed
12.
Soiffer RJ, Caligiuri MA, Tondini C, Canellos GP (1989) High-dose cytosine arabinoside in relapsed and refractory non-Hodgkin’s lymphoma. Limited role as a single agent. Cancer 64(10):2014–2018PubMedCrossRef
13.
Chau I, Harries M, Cunningham D, Hill M, Ross PJ, Archer CD et al (2003) Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin’s and non-Hodgkin’s lymphoma. Br J Haematol 120(6):970–977PubMedCrossRef
14.
Crump M, Baetz T, Couban S, Belch A, Marcellus D, Howson-Jan K et al (2004) Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer 101(8):1835–1842PubMedCrossRef
15.
Ng M, Waters J, Cunningham D, Chau I, Horwich A, Hill M et al (2005) Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer 92:1352–1357
16.
Germann N, Brienza S, Rotarski M, Emile JF, Di Palma M, Musset M et al (1999) Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin’s lymphoma patients. Ann Oncol 10(3):351–354PubMedCrossRef
17.
Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E (2002) Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 1(3):227–235PubMed
18.
Oki Y, McLaughlin P, Pro B, Hagemeister FB, Bleyer A, Loyer E et al (2005) Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma. Cancer 104(4):781–787PubMedCrossRef
19.
Faivre S, Raymond E, Woynarowski JM, Cvitkovic E (1999) Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 44(2):117–123PubMedCrossRef
20.
Kollmannsberger C, Beyer J, Liersch R, Schoeffski P, Metzner B, Hartmann JT et al (2004) Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 22(1):108–114PubMedCrossRef
21.
Bidoli P, Stani SC, Mariani L, De Candis D, Cortinovis D, Aglione S et al (2004) Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer. Lung Cancer 43(2):203–208PubMedCrossRef
22.
Corazzelli G, Capobianco G, Frigeri F, Russo F, Pinto A (2002) Combination of gemcitabine and oxaliplatin (GEMOX) in refractory and relapsed NHL. Ann Oncol 13(Suppl 2):555a
23.
Woehrer S, Hejna M, Skrabs C, Drach J, Zielinski CC, Jaeger U et al (2005) Rituximab, Ara-C, dexamethasone and oxaliplatin is safe and active in heavily pretreated patients with diffuse large B-cell lymphoma. Oncology 69(6):499–502PubMedCrossRef
24.
Emmanouilides C, Jazirehi AR, Bonavida B (2002) Rituximab-mediated sensitization of B-non-Hodgkin’s lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine. Cancer Biother Radiopharm 17(6):621–630PubMedCrossRef
25.
Smith MR, Joshi I, Jin F, Obasaju C (2005) Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin’s lymphoma cell lines in vitro and in scid mice. BMC Cancer 5:103PubMedCrossRef
26.
El Gnaoui T, Dupuis J, Belhadj K, Jais JP, Rahmouni A, Copie-Bergman C et al (2007) Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol 18(8):1363–1368PubMedCrossRef
27.
Lopez A, Gutierrez A, Palacios A, Blancas I, Navarrete M, Morey M et al (2008) GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study. Eur J Haematol 80(2):127–132PubMedCrossRef
28.
Cabanillas F, Liboy I, Rodriguez-Monge E, Pavia O, Robles N, Maldonado N et al (2008) GROC (gemcitabine, rituximab, oxaliplatin combination) plus pegfilgrastim is less toxic and as active as DHAP and ESHAP for relapsed aggressive non-Hodgkin’s lymphoma (NHL). J Clin Oncol 26(suppl) (abstract 8530)
29.
Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J et al (2000) The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting–Airlie House, Virginia, November, 1997. Hematol J 1(1):53–66PubMedCrossRef
30.
Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17(4):1244PubMed
31.
Hryniuk WM, Goodyear M (1990) The calculation of received dose intensity. J Clin Oncol 8:1935–1937PubMed
32.
Marce S, Molina-Arcas M, Villamor N, Casado FJ, Campo E, Pastor-Anglada M et al (2006) Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. Haematologica 91(7):895–902PubMed
33.
Ortega-Paino E, Fransson J, Ek S, Borrebaeck CA (2008) Functionally associated targets in mantle cell lymphoma as defined by DNA microarrays and RNA interference. Blood 111(3):1617–1624PubMedCrossRef
34.
Rodriguez J, Gutierrez A, Palacios A, Navarrete M, Blancas I, Alarcon J et al (2007) Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma. Leuk Lymphoma 48(11):2172–2178PubMedCrossRef
35.
El Gnaoui T, Dupuis J, Joly B, Belhadj K, Rahmouni A, Copie-Bergman C et al (2004) Rituximab, gemcitabine and oxaliplatin (R-GEMOX): a promising regimen for refractory/relapsed B-Cell lymphoma. Blood 104(11):2483a
36.
Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV et al (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35(1):1–39PubMed
37.
Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E et al (2008) Six versus eight cycles of bi-weekly CHOP–14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 9(2):105–116PubMedCrossRef
38.
Sirohi B, Cunningham D, Norman A, Last K, Chau I, Horwich A et al (2007) Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL). Hematology 12(2):149–153PubMedCrossRef
39.
Morschhauser F, Depil S, Jourdan E, Wetterwald M, Bouabdallah R, Marit G et al (2007) Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma. Ann Oncol 18(2):370–375PubMedCrossRef
40.
Jacobs SS, Fox E, Dennie C, Morgan LB, McCully CL, Balis FM (2005) Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates. Clin Cancer Res 11(4):1669–1674PubMedCrossRef
41.
Kerr JZ, Berg SL, Dauser R, Nuchtern J, Egorin MJ, McGuffey L et al (2001) Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates. Cancer Chemother Pharmacol 47(5):411–414PubMedCrossRef
42.
Bjorkholm M, Hagberg H, Holte H, Kvaloy S, Teerenhovi L, Anderson H et al (2007) Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up. Ann Oncol 18(6):1085–1089PubMedCrossRef
43.
Lokiec F (2006) Ifosfamide: pharmacokinetic properties for central nervous system metastasis prevention. Ann Oncol 17(Suppl 4):iv33–iv36PubMedCrossRef
44.
Corazzelli G, Russo F, Capobianco G, Marcacci G, Della Cioppa P, Pinto A (2006) Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin’s lymphoma: results of a pilot study. Ann Oncol 17(Suppl 4):iv18–iv24PubMedCrossRef
45.
Corazzelli G, Capobianco G, Marcacci G, Frigeri F, Arcamone M, Becchimanzi C et al (2008) Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective salvage regimen for relapsed and refractory Hodgkin and non-Hodgkin’s lymphoma: results of a pilot study. Ann Oncol 19(supplement 4):iv235
Metadata
Title
Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma
Authors
Gaetano Corazzelli
Gaetana Capobianco
Manuela Arcamone
Pier Ferruccio Ballerini
Emilio Iannitto
Filippo Russo
Ferdinando Frigeri
Cristina Becchimanzi
Gianpaolo Marcacci
Annarosaria De Chiara
Antonio Pinto
Publication date
01-10-2009
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 5/2009
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-009-0941-9

Other articles of this Issue 5/2009

Cancer Chemotherapy and Pharmacology 5/2009 Go to the issue

Original Article

Delivery of high levels of anti-proliferative nucleoside triphosphates to CYP3A-expressing cells as a potential treatment for hepatocellular carcinoma

Original Article

Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer

Original Article

Analysis of feasibility and toxicity of concurrent chemoradiotherapy with S-1 for locally advanced squamous cell carcinoma of the head and neck in elderly cases and/or cases with comorbidity

Original Article

Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function

Original Article

The acute effects of CMF-based chemotherapy on maxillary periodontal microcirculation

Original Article

The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits